Tesamorelin and IGF-1 LR3 Together: What Is Known
Tesamorelin and IGF-1 LR3 taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 1 result, 2 Oct 2026).
Side by side
Showing 11 of 13 fields where the two differ. Category, PCAC vote, Jul 2026 are the same or both unknown.
| Field | Tesamorelin | IGF-1 LR3 |
|---|---|---|
| Class | GHRH analog | IGF-1 analog |
| Also called | tesa, Egrifta | LR3 |
| Category | Growth hormone | Growth hormone |
| FDA status | FDA approved (Egrifta) | Not FDA approved · research chemical |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. | Prohibited by WADA (S2.3)IGF-1 and its analogues (LR3 is an IGF-1 analogue) are prohibited in S2.3, at all times. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) | 563 min half-life in wound fluid (versus 872 min for IGF-I)wound chamber (rat) (rat) · The American journal of physiology 1999, PMID 10198302 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 | Human observational evidence, 3 of 4Strongest: Growth hormone & IGF research 2010, PMID 20675162 |
| Human studies we summarised | 12 human (11 randomized or controlled) of 16 summarised | 1 human (0 randomized or controlled) of 12 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg, 20 mg | 0.1 mg, 1 mg |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026) | Not in the letters we track |
Tesamorelin vs IGF-1 LR3
Choosing between the two rather than combining them? The comparison lines them up field by field.
Tesamorelin raises IGF-1, and the label says to watch it
The Egrifta label says tesamorelin increases serum IGF-1, and tells prescribers to monitor IGF-1 because prolonged elevation effects are unknown.[5]
In a 52-week extension in HIV patients, the visceral fat change with tesamorelin was sustained at -18%.[17]
A randomized trial found tesamorelin reduced liver fat in HIV by an absolute -4.1%.[7]
IGF-1 LR3 is animal data
In rats, LR3IGF-I but not IGF-I increased small and large intestine weight by +20%.[18]
Another rat study found LR3-IGF-I had no positive effect on carcass protein accretion, alone or with insulin.[19]
Glucose warning on the tesamorelin label
Egrifta's label adds that tesamorelin may bring on glucose intolerance, with glucose to be evaluated before and during therapy.[5]
Together
The tesamorelin with IGF-1 LR3 search returned 1 PubMed record, not classed as a study of both.
Calculated from pubmed query ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]); search date 2026-10-02; records returned 1; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key igf-1-lr3__tesamorelin); no arithmetic applied.
IGF-1, also called mecasermin, is named on WADA's list along with its analogues.[2]
Common questions
Tesamorelin vs IGF-1 LR3: which is better?
They work at different points; tesamorelin stimulates GH production and so raises IGF-1, whereas LR3 is an IGF-1 analogue studied in animals.[5]
Can you stack tesamorelin with IGF-1 LR3?
No study of the pair was found, and the tesamorelin label already tells prescribers to monitor IGF-1 elevations.[5]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 5EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 7Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 8The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 9Clearance of IGFs and insulin from wounds: effect of IGF-binding protein interactions.The American journal of physiology · 1999PMID 10198302Accessed 2 Oct 2026
- 10Detection of His-tagged Long-R³-IGF-I in a black market product.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2010PMID 20675162Accessed 2 Oct 2026
- 11IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.American journal of physiology. Endocrinology and metabolism · 2025PMID 39679943Accessed 2 Oct 2026
- 12Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.Journal of Alzheimer's disease : JAD · 2025PMID 39610283Accessed 2 Oct 2026
- 13Insulin-like growth factor-I and analogues increase growth in artificially-reared neonatal pigs.The British journal of nutrition · 2002PMID 12067429Accessed 2 Oct 2026
- 14PubMed search: ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 16Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.The Biochemical journal · 1993PMID 7683875Accessed 2 Oct 2026
- 17Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS (London, England) · 2008PMID 18690162Accessed 2 Oct 2026
- 18Administration of insulin-like growth factor-I (IGF-I) peptides for three days stimulates proliferation of the small intestinal epithelium in rats.Gut · 1995PMID 8549937Accessed 2 Oct 2026
- 19Effects of insulin and insulin-like growth factors on protein and energy metabolism in tumour-bearing rats.The Biochemical journal · 1994PMID 8053901Accessed 2 Oct 2026
Found an error? Report a correction.